AU2003291365B2 - Compositions and methods for treating or preventing pneumococcal infection - Google Patents

Compositions and methods for treating or preventing pneumococcal infection Download PDF

Info

Publication number
AU2003291365B2
AU2003291365B2 AU2003291365A AU2003291365A AU2003291365B2 AU 2003291365 B2 AU2003291365 B2 AU 2003291365B2 AU 2003291365 A AU2003291365 A AU 2003291365A AU 2003291365 A AU2003291365 A AU 2003291365A AU 2003291365 B2 AU2003291365 B2 AU 2003291365B2
Authority
AU
Australia
Prior art keywords
polypeptide
immune response
seq
mammal
streptococcus pneumoniae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003291365A
Other languages
English (en)
Other versions
AU2003291365A1 (en
Inventor
Dong-Sheng Chen
Michael C. Chen
Chuang-Jiun Chiou
Zhongming Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synergy America Inc
Original Assignee
Synergy America Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synergy America Inc filed Critical Synergy America Inc
Publication of AU2003291365A1 publication Critical patent/AU2003291365A1/en
Application granted granted Critical
Publication of AU2003291365B2 publication Critical patent/AU2003291365B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003291365A 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection Expired AU2003291365B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42449702P 2002-11-07 2002-11-07
US60/424,497 2002-11-07
PCT/US2003/035529 WO2004043376A2 (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Publications (2)

Publication Number Publication Date
AU2003291365A1 AU2003291365A1 (en) 2004-06-03
AU2003291365B2 true AU2003291365B2 (en) 2009-06-11

Family

ID=32312819

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003291365A Expired AU2003291365B2 (en) 2002-11-07 2003-11-06 Compositions and methods for treating or preventing pneumococcal infection

Country Status (10)

Country Link
US (2) US7217791B2 (https=)
EP (1) EP1558280B1 (https=)
JP (3) JP2006506989A (https=)
KR (1) KR20050086427A (https=)
CN (1) CN100443116C (https=)
AU (1) AU2003291365B2 (https=)
CA (1) CA2504938C (https=)
ES (1) ES2451620T3 (https=)
TW (1) TWI315986B (https=)
WO (1) WO2004043376A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008287286B2 (en) 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2252326A4 (en) * 2008-02-01 2012-08-29 Newcastle Innovation Ltd VACCINE COMPOSITIONS
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2833409A1 (en) * 2011-04-21 2012-10-26 The Rockefeller University Streptococcus bacteriophage lysins for detection and treatment of gram positive bacteria
CN103533953A (zh) 2011-05-17 2014-01-22 葛兰素史密丝克莱恩生物有限公司 针对肺炎链球菌的疫苗
EP2764093B1 (en) * 2011-10-05 2018-04-18 The Rockefeller University Dimeric bacteriophage lysins
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP4501949A3 (en) 2014-11-21 2025-04-30 The Board of Regents of the University of Oklahoma Pneumolysin mutants and methods of use thereof
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687688A1 (en) * 1993-12-17 1995-12-20 Universidad De Oviedo Antibodies against pneumolysine and their applications
WO1999003884A2 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6342224B1 (en) * 1997-08-22 2002-01-29 Smithkline Beecham Biologicals, S.A. Recombinant papillomavirus vaccine and method for production and treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006951A1 (en) 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
ATE361365T1 (de) * 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
EP1169465B1 (en) * 1998-12-04 2006-03-01 University Of Manitoba Two-step immunization procedure against chlamydia infection
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
ES2258987T3 (es) * 1999-12-17 2006-09-16 Wyeth Holdings Corporation Vacuna para reforzar las respuestas inmunitarias al virus del herpes simple.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0687688A1 (en) * 1993-12-17 1995-12-20 Universidad De Oviedo Antibodies against pneumolysine and their applications
WO1999003884A2 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6342224B1 (en) * 1997-08-22 2002-01-29 Smithkline Beecham Biologicals, S.A. Recombinant papillomavirus vaccine and method for production and treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
(X) McDaniel et. al. Gene Therapy 4(4):375-7 (1997) *

Also Published As

Publication number Publication date
US20080199952A1 (en) 2008-08-21
CN100443116C (zh) 2008-12-17
WO2004043376A2 (en) 2004-05-27
JP2010057501A (ja) 2010-03-18
EP1558280A2 (en) 2005-08-03
CN1711105A (zh) 2005-12-21
TW200418502A (en) 2004-10-01
CA2504938A1 (en) 2004-05-27
JP2006506989A (ja) 2006-03-02
US7585669B2 (en) 2009-09-08
WO2004043376A3 (en) 2004-10-14
CA2504938C (en) 2011-10-11
JP2012139221A (ja) 2012-07-26
EP1558280A4 (en) 2007-08-29
AU2003291365A1 (en) 2004-06-03
US20040213803A1 (en) 2004-10-28
KR20050086427A (ko) 2005-08-30
ES2451620T3 (es) 2014-03-28
EP1558280B1 (en) 2014-01-08
HK1074005A1 (en) 2005-10-28
TWI315986B (en) 2009-10-21
US7217791B2 (en) 2007-05-15

Similar Documents

Publication Publication Date Title
US7585669B2 (en) Compositions and methods for treating or preventing pneumococcal infection
US5786189A (en) Vaccine
US20180140666A1 (en) Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
AU2022201940B2 (en) Vaccination with MICA/B alpha 3 domain for the treatment of cancer
US20100260802A1 (en) RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE
US6716432B1 (en) Pneumolysin mutants and pneumococcal vaccines made therefrom
CN110845587A (zh) 一种定点突变的载体蛋白及其在制备疫苗中的用途
AU644828B2 (en) Novel vaccine
HK1074005B (en) Compositions and methods for treating or preventing pneumococcal infection
CA2488234A1 (en) Immunomodulatory constructs and their uses
AU2003204215B2 (en) Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
AU722078B2 (en) Conjugate vaccine against group B Streptococcus
HK1004569B (en) Novel vaccine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired